The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
Shulman
Lee P
LP
Section of Reproductive Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D001943:Breast Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects*; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects; D019317:Evidence-Based Medicine; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage / Q000009:adverse effects; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014481:United States; D016387:Women's Health
D003271:Contraceptive Agents, Female; D004967:Estrogens; D004958:Estradiol; D016912:Levonorgestrel